Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 3
1987 2
1988 2
1989 2
1990 9
1991 3
1992 9
1993 9
1994 8
1995 7
1996 5
1997 5
1998 10
1999 7
2000 14
2001 12
2002 17
2003 20
2004 48
2005 137
2006 182
2007 211
2008 199
2009 254
2010 330
2011 450
2012 485
2013 692
2014 739
2015 859
2016 861
2017 852
2018 932
2019 935
2020 985
2021 1022
2022 1022
2023 916
2024 330

Text availability

Article attribute

Article type

Publication date

Search Results

11,034 results

Results by year

Filters applied: . Clear all
Page 1
EGFR mutations and lung cancer.
da Cunha Santos G, Shepherd FA, Tsao MS. da Cunha Santos G, et al. Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206. Annu Rev Pathol. 2011. PMID: 20887192 Review.
Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors. Inhibitors that target the kinase domain of EGFR have been developed and are clinically active …
Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic tar …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.
Fu K, Xie F, Wang F, Fu L. Fu K, et al. J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4. J Hematol Oncol. 2022. PMID: 36482474 Free PMC article. Review.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting …
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung …
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Leonetti A, et al. Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30. Br J Cancer. 2019. PMID: 31564718 Free PMC article. Review.
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer ( …
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly sel …
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Harrison PT, Vyse S, Huang PH. Harrison PT, et al. Semin Cancer Biol. 2020 Apr;61:167-179. doi: 10.1016/j.semcancer.2019.09.015. Epub 2019 Sep 25. Semin Cancer Biol. 2020. PMID: 31562956 Free PMC article. Review.
Classical activating mutations (exon 19 deletions and the L858R point mutation) comprise the vast majority of EGFR mutations and are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors (EGFRi). ...Despite an increased upta …
Classical activating mutations (exon 19 deletions and the L858R point mutation) comprise the vast majority of EGFR mutations and are …
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
Brazel D, Kroening G, Nagasaka M. Brazel D, et al. BioDrugs. 2022 Nov;36(6):717-729. doi: 10.1007/s40259-022-00556-4. Epub 2022 Oct 18. BioDrugs. 2022. PMID: 36255589 Free PMC article. Review.
Molecular testing is performed upon diagnosis of non-small cell lung cancer (NSCLC) because of the large success of targeted therapies for oncogenic mutations. Epidermal growth factor receptor (EGFR) mutations are the most commonly identified mutation in NSCLC, and EGFR …
Molecular testing is performed upon diagnosis of non-small cell lung cancer (NSCLC) because of the large success of targeted therapies for o …
Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.
Liu Y. Liu Y. Cancer Biol Ther. 2018 Jun 3;19(6):445-449. doi: 10.1080/15384047.2018.1435222. Epub 2018 Mar 6. Cancer Biol Ther. 2018. PMID: 29461911 Free PMC article. Review.
Epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly improved the response of non-small cell lung cancer (NSCLC) with EGFR-mutant patients. However, these patients inevitably come cross acquired resistance to EGFR-TKIs. The t …
Epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly improved the response of non-small cell lung c …
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Wu SG, Shih JY. Wu SG, et al. Mol Cancer. 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1. Mol Cancer. 2018. PMID: 29455650 Free PMC article. Review.
EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. ...
EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung can …
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.
Castellanos E, Feld E, Horn L. Castellanos E, et al. J Thorac Oncol. 2017 Apr;12(4):612-623. doi: 10.1016/j.jtho.2016.12.014. Epub 2016 Dec 23. J Thorac Oncol. 2017. PMID: 28017789 Free article. Review.
EGFR-mutated NSCLC is a genetically heterogeneous disease that includes more than 200 distinct mutations. ...Additionally, 10% of patients will have an uncommon EGFR mutation, and response to EGFR TKI therapy is highly variable depending on the mutation. ...
EGFR-mutated NSCLC is a genetically heterogeneous disease that includes more than 200 distinct mutations. ...Additionally, 10% of pat …
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Yasuda H, Kobayashi S, Costa DB. Yasuda H, et al. Lancet Oncol. 2012 Jan;13(1):e23-31. doi: 10.1016/S1470-2045(11)70129-2. Epub 2011 Jul 19. Lancet Oncol. 2012. PMID: 21764376 Review.
EGFR exon 20 insertion mutations, which are typically located after the C-helix of the tyrosine kinase domain of EGFR, may account for up to 4% of all EGFR mutations. ...Growing clinical experience with patients whose tumours harbour EGFR exon 20 inser …
EGFR exon 20 insertion mutations, which are typically located after the C-helix of the tyrosine kinase domain of EGFR, may acc …
Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.
Araki T, Kanda S, Horinouchi H, Ohe Y. Araki T, et al. Jpn J Clin Oncol. 2023 Jun 29;53(7):547-561. doi: 10.1093/jjco/hyad052. Jpn J Clin Oncol. 2023. PMID: 37279591 Free PMC article. Review.
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study. ...This review describes current pharmacotherapeutic strategies for EGFR-mutated n …
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated EGFR-mutated non-small cell lung ca …
11,034 results
You have reached the last available page of results. Please see the User Guide for more information.